
Currently out of the existing stock ratings of Liav Abraham, 18 are a HOLD (21.95%), 62 are a BUY (75.61%), 2 are a SELL (2.44%).
Analyst Liav Abraham, currently employed at CITI, has had 63.12% of price targets met with an average potential upside of 20.21%, reached in 655 days on average.
Liav Abraham has documented 163 price targets and ratings displayed on 14 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on TEVA, Teva Pharma Industries Ltd ADR at 30-Apr-2021.
Analyst best performing recommendations are on ELAN (ELANCO ANIMAL HEALTH).
The best stock recommendation documented was for TEVA (TEVA PHARMA INDUSTRIES LTD ADR) on 5/1/2018. The price target of $24 was fulfilled within 42 days with a profit of $5.29 (28.27%), with a performance score of 6.73.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 21-Dec-2016
$193
$202
6 years 7 months 1 days ago
(21-Apr-2020)
4/12 (33.33%)
$8.96 (4.87%)
141
Hold Since 08-May-2019
$203
$178
6 years 9 months 12 days ago
(10-Feb-2020)
5/19 (26.32%)
$4.87 (2.46%)
74
Buy Since 03-Aug-2017
$198
$184
6 years 10 months ago
(22-Jan-2020)
5/14 (35.71%)
$7.8 (4.10%)
134
Buy Since 03-Aug-2015
$200
7 years 3 days ago
(19-Nov-2019)
2/12 (16.67%)
$73.92 (58.63%)
290
Hold Since 19-Nov-2019
$203
$189
7 years 3 days ago
(19-Nov-2019)
1/2 (50%)
$19.19 (10.44%)
96
Stocks Liav Abraham covered previously. Scores are shown for active stocks only.
The record of these past calls is part of the data set at anachart.store.
What Year was the first public recommendation made by Liav Abraham?